Piramal Pharma Limited (PPL) announced its Q3 FY26 results, reporting a 3% YoY decrease in revenue to ₹2,140 crore, impacted by inventory destocking and slower order inflows. EBITDA decreased by 32% to ₹239 crore. The company sees early signs of recovery in order inflows since October 2025 and expects Q4 to be the strongest quarter. PPL is investing in capacity expansion and new products.
Financial Performance Overview
Piramal Pharma Limited (PPL) announced its consolidated results for Q3 FY26, ended December 31, 2025. Key highlights include:
- Revenue from Operations: ₹2,140 crore, a decrease of 3% YoY.
- EBITDA: ₹239 crore, a decrease of 32% YoY.
- PAT After Exceptional Items: ₹(136) crore.
Segmental Performance
CDMO Business
The CDMO business reported revenue of ₹1,166 crore, a decrease of 9% YoY, impacted by inventory destocking and slower early-stage order inflows. However, the company is seeing significant pick-up in RFPs and order inflow since October 2025.
Complex Hospital Generics (CHG)
The CHG business reported revenue of ₹668 crore, an increase of 2% YoY. The company has entered into an agreement to acquire Kenalog® from Bristol-Myers Squibb.
Piramal Consumer Healthcare (PCH)
The PCH business reported revenue of ₹334 crore, an increase of 20% YoY. Power Brands grew strongly, contributing to 51% of total PCH sales.
Key Business Updates
- Biopharma Funding: Signs of recovery in H2CY25.
- CDMO Expansion: US$ 90Mn investment to expand Lexington and Riverview facilities, on track.
- CHG Acquisition: Entered into an agreement to acquire Kenalog® from Bristol-Myers Squibb.
Sustainability Initiatives
Piramal Pharma is committed to responsible operations. Key sustainability highlights include:
- 42% reduction in absolute Scope 1 & 2 emissions by FY2030 (Baseline: FY2022).
- 25% reduction in Scope 3 emissions aligned with SBTi methodology by FY2030 (Baseline: FY2022).
Source: BSE
